Navigation Links
Optimer Pharmaceuticals to Present at the Canaccord Genuity Annual Growth Conference
Date:8/1/2011

SAN DIEGO, Aug. 1, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced that the Company will present at the Canaccord Genuity Annual Growth Conference on August 10, 2011 at 11:30 a.m. Eastern Time at the InterContinental Hotel in Boston.

(Logo:  http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

A live audio webcast of this presentation will be accessible in the Investors section of the Company's website at www.optimerpharma.com. Replays of this presentation will be available at the same location for 30 days following the meeting.

About Optimer Pharmaceuticals

Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative hospital specialty products that have a positive impact on society. Optimer developed and is commercializing DIFICID™ (fidaxomicin) Tablets, an FDA approved antibacterial drug for the treatment of adult patients with Clostridium difficile-associated diarrhea (CDAD). Optimer has filed a marketing authorization application with the European Medicines Agency for fidaxomicin. Optimer's clinical pipeline includes Pruvel™, a product in the fluoroquinolone class of antibiotics that has completed Phase 3 trials as a treatment for infectious diarrhea. Additional information can be found at http://www.optimerpharma.com.

Contacts:
Optimer Pharmaceuticals, Inc.
David Walsey, Vice President, Investor Relations and Corporate Communications
858-909-0736

Canale Communications, Inc.
Jason I. Spark, Senior Vice President
619-849-6005


'/>"/>
SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Optimer Pharmaceuticals and Clinical Investigators to Present Data at Upcoming Medical Meetings
2. Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
3. Optimer Pharmaceuticals, Inc. Announces Exercise in Full of Underwriters Option to Purchase Additional Shares and Closing of Public Offering of Common Stock
4. Optimer Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
5. Optimer Pharmaceuticals to Present at Oppenheimer Healthcare Conference
6. Optimer Pharmaceuticals Announces Presentations at Upcoming IDSA Annual Meeting
7. Optimer Announces Presentation of Additional Data from Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection (CDI) Presented at ICAAC
8. Optimer Pharmaceuticals Phase 3 Clinical Trials show Fidaxomicin is Superior to Vancomycin in Treatment of Recurrent Clostridium difficile Infection (CDI); Data Presented at ICAAC
9. Optimer Pharmaceuticals Reports Third Quarter 2009 Financial Results
10. Optimer Pharmaceuticals to Present at September 2009 Investor Conferences
11. Optimer Pharmaceuticals Announces Presentations of Additional Phase 3 Fidaxomicin and Prulifloxacin Data at Upcoming ICAAC Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... August 01, 2014 Once a decision ... cost? This webinar will discuss how to define your ... Join speakers Bob Allen, Senior Director of Facilities Integration ... Engineering at Fluor Industrial Services, and special guest Carrier ... Planning at Amgen, as they provide an examination of ...
(Date:8/1/2014)... Aug. 1, 2014 Glencoe Software, ... of "Data InPress" ( http://glencoesoftware.com/data-inpress.html ), a ... multidimensional image data into on-line publications.  The ... Video Injection Service. Photo - ... http://photos.prnewswire.com/prnh/20140731/132409 The DataViewer ...
(Date:7/31/2014)... “2014 Deep Research Report ... is a professional and in-depth research report ... Polyurethane Resin basic information, including its definition, ... industry overview. This research covers the international ... well as global industry analysis covering macroeconomic ...
(Date:7/31/2014)... not donor candidates for bone marrow transplantation. The immune ... prone to life-threatening infection and other maladies, and a ... reason why. , "We have found the cellular mechanism ... blood production over time in an old organism, and ... rejuvenation therapies," said Emmanuelle Passegu, PhD, a professor of ...
Breaking Biology Technology:Defining Low Cost in Your Solution for Future Facilities, New Webinar for Pharma, Biotech, Medical Device and Healthcare Companies, Hosted by Xtalks 2Glencoe Software Launches Data InPress 2Glencoe Software Launches Data InPress 3Polyurethane Resin Industry & Thermoplastic Polyurethane Market (China, Global) Analysis Now at DeepResearchReports.com 2Polyurethane Resin Industry & Thermoplastic Polyurethane Market (China, Global) Analysis Now at DeepResearchReports.com 3Polyurethane Resin Industry & Thermoplastic Polyurethane Market (China, Global) Analysis Now at DeepResearchReports.com 4Key to aging immune system is discovered 2
... Ill., Sept. 17 Baxter,International (NYSE: BAX ), ... quarter 2008 financial results on Thursday, October 16, 2008, ... access the call, please,dial 866- 238-0637 (domestic) or 703-639-1156 ... prior to the start of the call for the,operator ...
... (Amex: SYI ) today announced that a Letter ... http://www.synvista.com . The,text is as follows:, To ... made tremendous progress in our,efforts to deliver on the ... cardiovascular disease in diabetics as well as the,treatment of ...
... a systems,biology company focused on identifying molecular mechanisms, ... molecular diagnostics,announced today that it has appointed Louis ... executive management team, Mr. Latino will lead the,company,s ... sales,infrastructure to drive future growth., In his ...
Cached Biology Technology:Baxter International Third Quarter 2008 Financial Results Conference Call 2Synvista Therapeutics Posts Letter to Stockholders on Web Site 2Synvista Therapeutics Posts Letter to Stockholders on Web Site 3Synvista Therapeutics Posts Letter to Stockholders on Web Site 4Synvista Therapeutics Posts Letter to Stockholders on Web Site 5Synvista Therapeutics Posts Letter to Stockholders on Web Site 6Genstruct Names Louis Latino VP of Sales 2Genstruct Names Louis Latino VP of Sales 3
(Date:8/1/2014)... been recorded into the Reptile Database, a web-based ... making the reptile species among the most diverse ... fish species. , For some time, experts have ... reptiles would become the most diverse vertebrate group ... crocodiles, tuataras and amphisbaenians. , "Officially, we have ...
(Date:8/1/2014)... Professor Charan Ranganath of the UC Davis Center ... a National Security Science and Engineering Faculty Fellowship ... $2.6 million fellowship will support new work on ... at UC Davis. , The new project aims ... understood, with activity in the cortex and hippocampus, ...
(Date:8/1/2014)... confused group of marine mammals have officially named ... dolphin, Sousa sahulensis , according to the ... The study describing the newly named species is ... of all available historical records, physical descriptions, and ... coastal cetaceans ranging from the coast of West ...
Breaking Biology News(10 mins):Reptile Database surpasses 10,000 reptile species 2Reptile Database surpasses 10,000 reptile species 3Scientists name new species of cetacean: The Australian humpback dolphin 2Scientists name new species of cetacean: The Australian humpback dolphin 3
... The Howard Hughes Medical Institute (HHMI) and the Gordon ... Martienssen, Ph.D., of Cold Spring Harbor Laboratory (CSHL) to ... fundamental plant science. Dr. Martienssen is one of 15 ... been named HHMI-GBMF Investigators in plant sciences. ...
... uncovered the defect behind a rare hereditary children,s disease ... D. This discovery has led researchers to develop the ... disease. Idiopathic Infantile Hypercalcemia (IIH) is among the ... that one in every 47,000 people around 600 ...
... the U.S. biomedical device industry unveiled today a national ... development of devices with great clinical utility, quality and ... key component of the nation,s drive to bolster its ... device innovation that improves human health, the leaders said. ...
Cached Biology News:CSHL professor Rob Martienssen receives prestigious appointment as HHMI-GBMF investigator 2CSHL professor Rob Martienssen receives prestigious appointment as HHMI-GBMF investigator 3CSHL professor Rob Martienssen receives prestigious appointment as HHMI-GBMF investigator 4U.S. Biomedical Leaders Present a New National Device Innovation Strategy Based on "Value-driven Engineering" 2U.S. Biomedical Leaders Present a New National Device Innovation Strategy Based on "Value-driven Engineering" 3U.S. Biomedical Leaders Present a New National Device Innovation Strategy Based on "Value-driven Engineering" 4
... Software reads and processes raw ... microarray data for analysis. ... one 2-year license for Feature ... , * one CD-ROM ...
... and SYBR Safe DNA Gel Stain combo offers these ... buying these same products separately ... bromide Eliminates risks to ... and RNA fragments from 100 bp to >30 kb. ...
Anti-WT-1 Liquid. In 10 μM PBS, 0.2 % BSA, pH 7.6. Recognizes the ~47-55 kDa Wilm's tumor protein in Wilm's tumor tissue. ...
... The economical ICS-90 uses continuous chemical ... to give you fast, accurate determinations of ... ranges. Easy to operate, quick to equilibrate, ... the compact ICS-90 helps you achieve maximum ...
Biology Products: